Sun Pharma wins LEQSELVITM injunction appeal in US

Sun Pharmaceutical Industries announced today that the U.S. Court of Appeals for the Federal Circuit ruled in its favor, vacating a preliminary injunction that had been delaying the launch of LEQSELVITM (deuruxolitinib) in the United States. The decision, made on April 9, 2025, shortly after oral arguments, effectively removes the court-imposed barrier and allows Sun Pharma to move forward with its launch plans. The company will disclose LEQSELVITM launch plans in due course. The legal proceedings between Incyte Corporation and Sun Pharma continue.